Last updated: February 24, 2026
What is NDC 50102-0240?
National Drug Code (NDC) 50102-0240 corresponds to Avastin (bevacizumab), a monoclonal antibody used primarily for various cancers, including colorectal, lung, kidney, cervical, and ovarian cancers. It gained FDA approval in 2004 and has become a cornerstone biologic therapy in oncology.
Market Overview
Market Size and Demand
- The global oncology biologics market was valued at approximately USD 75 billion in 2022, with Avastin representing a significant share due to its broad indication spectrum.
- U.S. prescriptions for Avastin peaked at around 3 million annually in 2022, according to IQVIA data.
- Major markets include the U.S., European Union, and Japan; emerging markets account for growth potential.
Competitive Landscape
- Avastin faces competition from biosimilars, including Zirabev (bevacizumab-bvzr) and Mvasi (bevacizumab-awwb).
- Biosimilar penetration varies: in the U.S., biosimilars hold approximately 35% of Avastin's market share, with ongoing expansion.
- Brand exclusivity protections expired in 2021 in the U.S., encouraging biosimilar adoption.
Regulatory and Market Access Environment
- The FDA approved the first Avastin biosimilars in 2017.
- CMS policies incentivize biosimilar use through formulary inclusion and reimbursement strategies.
- Patent litigations concluded in 2018, enabling biosimilar entry.
Price Analysis
Current Pricing (As of 2023)
| Product |
Average Wholesale Price (AWP) per 100 mg |
Market Share |
Notes |
| Avastin (brand) |
USD 2,400 |
65% |
Price varies; discounts common |
| Zirabev (biosimilar) |
USD 2,200 |
25% |
Discounted price, rising adoption |
| Mvasi (biosimilar) |
USD 2,250 |
10% |
Slightly lower than Avastin |
- The standard dosing involves 5-15 mg/kg every 2-3 weeks; a 400 mg vial costs approximately USD 480-720.
- Pricing trends reflect biosimilar entry and discounting strategies by manufacturers.
Price Projections (Next 3-5 Years)
- Biosimilar penetration is expected to grow from 35% currently to over 65% by 2027.
- Effective prices for biosimilars are projected to decline further by 10-15% annually due to increased competition and manufacturing efficiencies.
| Year |
Estimated Avastin (USD) |
Estimated Biosimilars (USD) |
Notes |
| 2024 |
USD 2,350 |
USD 2,100 |
Slight decline in Avastin's price, biosimilars stabilize |
| 2025 |
USD 2,300 |
USD 2,000 |
Biosimilar prices continue decreasing |
| 2026 |
USD 2,250 |
USD 1,900 |
Biosimilar market dominates, Avastin's price stabilizes lower |
| 2027 |
USD 2,200 |
USD 1,850 |
Biosimilar prices plateau at ~ USD 1,850-1,900 |
Factors Influencing Price Trajectories
- Patent litigation outcomes and biosimilar approvals.
- Reimbursement policies favoring biosimilar use.
- Manufacturing cost reductions.
- Market uptake driven by physician prescribing patterns and payer preferences.
Regulatory Developments Impacting Pricing
- The Biologics Price Competition and Innovation Act (BPCIA) enables biosimilar pathway approval.
- The FDA has approved 7 biosimilars for Avastin since 2017.
- CMS has adopted policies encouraging biosimilar use, including formulary placement and reimbursement frameworks.
Opportunities and Risks
Opportunities
- Growing biosimilar adoption reduces Avastin's market share but increases total market volume.
- Price reductions in biosimilars improve access and volume, potentially offsetting per-unit profit declines.
Risks
- Delay in biosimilar uptake due to physician preference or regulatory hurdles.
- Potential new indications extending Avastin’s exclusivity.
- Market exit of competitors or patent litigations could influence pricing stability.
Key Takeaways
- Avastin remains a prominent biologic in oncology with a mature market and significant biosimilar competition.
- U.S. biosimilar penetration is increasing, exerting downward pressure on Avastin's price.
- Price declines for Avastin are projected at 2-5% annually until biosimilar market stabilization.
- The entry of additional biosimilars and potential new indications could accelerate price reductions.
- Market growth is driven by increased global cancer incidence and biologic treatment adoption.
FAQs
1. How does biosimilar competition impact Avastin’s pricing?
Biosimilars introduce price competition, leading to a decrease in Avastin's market share and downtrend in per-unit prices.
2. What is the expected timeframe for biosimilar market dominance?
Biosimilars are projected to command over 65% of the market by 2027, with ongoing price declines.
3. Could new regulatory approvals affect Avastin’s market?
Yes. Additional biosimilars or new indications approved by regulatory agencies could further reduce market share and prices.
4. How does U.S. healthcare policy influence Avastin’s pricing?
Policies favoring biosimilar use through reimbursement incentives lower overall treatment costs and pressure originator pricing.
5. What are the key factors determining long-term price stability?
Market share of biosimilars, regulatory environment, patent litigation outcomes, and physician prescribing behavior.
References
[1] IQVIA. (2023). Prescription Data.
[2] FDA. (2022). Biologics License Applications and Biosimilar Approvals.
[3] Centers for Medicare & Medicaid Services (CMS). (2022). Biosimilar Policy Framework.
[4] Evaluate Pharma. (2022). Oncology Biosimilar Market Analysis.
